Literature DB >> 7520903

The pharmacokinetics of risperidone in humans: a summary.

J Heykants1, M L Huang, G Mannens, W Meuldermans, E Snoeck, L Van Beijsterveldt, A Van Peer, R Woestenborghs.   

Abstract

Risperidone is rapidly and completely absorbed after oral administration; less than 1% is excreted unchanged in the feces. The principal metabolite was found to be 9-hydroxyrisperidone. Hydroxylation of risperidone is subject to the same genetic polymorphism as debrisoquine and dextromethorphan. In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers. However, becuase the pharmacology of 9-hydroxyrisperidone is very similar to that of risperidone, the half-life for the "active fraction" (risperidone +9-hydroxyrisperidone) was found to be approximately 20 hours in extensive and poor metabolizers. We found that risperidone exhibited linear elimination kinetics and that steady state was reached within 1 day for risperidone and within 5 days for the active fraction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520903

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  43 in total

1.  Risperidone-related bilateral cystoid macular oedema.

Authors:  Kleanthis Manousaridis; Rajen Gupta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-06-12       Impact factor: 3.117

2.  Inhibition of cloned hERG potassium channels by risperidone and paliperidone.

Authors:  Hong Joon Lee; Jin-Sung Choi; Bok Hee Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-03-06       Impact factor: 3.000

3.  Development of controlled-release matrix tablet of risperidone: influence of Methocel®- and Ethocel®-based novel polymeric blend on in vitro drug release and bioavailability.

Authors:  Amir Badshah; Fazal Subhan; Khalid Rauf; Nadeem Irfan Bukhari; Kifayatullah Shah; Samiullah Khan; Zia Ahmed; Ihsanullah Khan
Journal:  AAPS PharmSciTech       Date:  2011-04-15       Impact factor: 3.246

4.  Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.

Authors:  B Cabovska; S L Cox; A A Vinks
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-15       Impact factor: 3.205

5.  Serum concentrations of paliperidone versus risperidone and clinical effects.

Authors:  Yasmin Nazirizadeh; Friederike Vogel; Wolfgang Bader; Ekkehard Haen; Bruno Pfuhlmann; Gerhard Gründer; Michael Paulzen; Markus Schwarz; Gerald Zernig; Christoph Hiemke
Journal:  Eur J Clin Pharmacol       Date:  2010-04-01       Impact factor: 2.953

6.  Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets.

Authors:  Ying Chen; Yang Deng; Miao Yan; Zhenyan Hou; Yao Li; Bikui Zhang; Hualin Cai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-08       Impact factor: 2.441

7.  Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults.

Authors:  Mona Darwish; Mary Bond; Ronghua Yang; Edward T Hellriegel; Philmore Robertson
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

8.  Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.

Authors:  Michael Paulzen; Ekkehard Haen; Benedikt Stegmann; Stefan Unterecker; Christoph Hiemke; Gerhard Gründer; Georgios Schoretsanitis
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-01       Impact factor: 5.270

9.  Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.

Authors:  Celine M Laffont; Roberto Gomeni; Bo Zheng; Christian Heidbreder; Paul J Fudala; Azmi F Nasser
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

10.  Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.

Authors:  Michael G Aman; Alexander A Vinks; Bart Remmerie; Erik Mannaert; Yaser Ramadan; Jessica Masty; Ronald L Lindsay; Krista Malone
Journal:  Clin Ther       Date:  2007-07       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.